Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells

Although non-small cell lung cancer (NSCLC) patients with EGFR mutation positive (EGFR M+) tumors initially respond well to EGFR tyrosine kinase inhibitor (TKI) monotherapy, the responses are usually incomplete. In this study we show that AKT inhibition, most importantly AKT2 inhibition, synergises...

Descripción completa

Detalles Bibliográficos
Autores principales: Bokobza, Sivan M., Jiang, Yanyan, Weber, Anika M., Devery, Aoife M., Ryan, Anderson J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4148097/
https://www.ncbi.nlm.nih.gov/pubmed/24946858

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4148097/
https://www.ncbi.nlm.nih.gov/pubmed/24946858

Ejemplares similares